<DOC>
	<DOC>NCT02316756</DOC>
	<brief_summary>This is first in human (FIH), double-blind, sponsor open, placebo-control trial to examine the safety, tolerability, pharmacokinetics and pharmacodynamics following a single ascending doses of PF-06648671 in healthy subjects.</brief_summary>
	<brief_title>A Single Ascending Dose Study To Evaluate Safety And Pharmacokinetics Of Compound PF-06648671 In Healthy Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subjects of non childbearing potential BMI of 17.5 to 30.5 kg/m2 and a total body weight &gt;50 kg (110 lbs) Evidence of a personally signed and dated informed consent document indicating that subject has been informed of all pertinent aspects of the study. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drg allergies, but excluding untreated asymptomatic, seasonal allergies at the time of dosing); Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 halflives preceding the first dose of study medication (whichever is longer) Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgement of the investigator, would make the subject inappropriate for entry into this study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Phase 1, Single-Dose Escalation, Double Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, PF-06648671, Plasma Abeta</keyword>
</DOC>